The prognosis of @entity5 is primarily dependent on its potential to invade and @entity3 . Data from both preclinical and clinical studies strongly suggest that @entity563 proteases, as well as their inhibitors and receptor, play a central role in the processes leading to @entity3 . We therefore investigated the prognostic value of plasminogen activator inhibitors type 1 ( @entity2289 ) and type 2 ( @entity10933 ) and the combination of both inhibitors in 332 @entity1 with operable @entity0 . @entity2289 and @entity10933 content was measured in the @entity5 cytosols using an enzyme-linked immunosorbent assay. For @entity2289 the median value (3.9 ng/mg protein) was used as cutoff, while the optimized cutoff for @entity10933 (6.5 ng/mg protein) was obtained using the log-rank statistic. After a median follow-up of 46 months 96 (29%) @entity1 relapsed. In univariate analysis @entity1 with a high @entity2289 or a low @entity10933 content had an increased risk of relapse. The difference was statistically significant for @entity2289 (p<0.0001) and almost statistically significant for @entity10933 (p=0.057). Stage, @entity5 size, differentiation grade, lymph node status and hormone receptor status also showed significant univariate impact on disease-free survival (DFS). In multivariate analysis (Cox model) @entity2289 (p<0.0001, RR=2.78), @entity10933 (p=0.0075, RR=2.17), UICC stage (p=0.0014, RR=2.2), differentiation grade (p=0.0097, RR=1.91) and nodal status (p<0.0001, RR=2.9) retained their significance. When both inhibitors were combined the worst prognosis was observed in @entity1 with simultaneous high @entity2289 and low @entity10933 levels, whereas low @entity2289 in combination with high @entity10933 values indicated a very favorable prognosis. In conclusion, our study showed that both @entity2289 and @entity10933 had independent prognostic value in @entity0 . Combination of both inhibitors further improved the differentiation of @entity1 with respect to prognosis.

Prognostic value of plasminogen activator inhibitors in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2289 :: ('5054', 'Gene') :: ['PAI-1'] @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'primary tumor'] @entity10933 :: ('5055', 'Gene') :: ['PAI-2'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastasize']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
